Especially since this is just the application for Breakthrough Therapy for Rett syndrome.
We still have Fragile X syndrome to come (which by the way is over 60x more common in the USA) - much wider market to sell to. And concussion after that.
The SP has essentially halved based on ~1/3 of NEU's possible business. Nothing is stopping NEU from gathering more evidence and applying again after speaking with the FDA. As mentioned by a previous poster a few days ago some other biotechs have had to apply 3 times before finally getting it.
Great buying op i think, or am i missing something?
Ann: Neuren receives response to request for Breakthrough Therapy, page-39
-
- There are more pages in this discussion • 19 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.61 |
Change
0.010(0.06%) |
Mkt cap ! $1.995B | |||
| Open | High | Low | Value | Volume |
| $15.64 | $15.93 | $15.44 | $8.412M | 538.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 558 | $15.59 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.66 | 1841 | 1 |
View Market Depth
| Last trade - 16.10pm 15/08/2024 (20 minute delay) ? |
| NEU (ASX) Chart |